Authors:
BEVERIDGE RA
MILLER JA
KALES AN
BINDER RA
ROBERT NJ
HARVEY JH
WINDSOR K
GORE I
CANTRELL J
THOMPSON KA
TAYLOR WR
BARNES HM
SCHIFF SA
SHIELDS JA
CAMBARERI RJ
BUTLER TP
MEISTER RJ
FEIGERT JM
NORGARD MJ
MORAES MA
HELVIE WW
PATTON GA
MUNDY LJ
HENRY D
MASON B
STADDON A
FORD P
KATCHER D
HOUCK W
MAJOR WB
GEMMA NW
KAY G
PRIEST E
SOWROY P
BANK B
LEIBACH S
REISEL H
GRAD G
WARREN RD
UENO WM
SMITH LF
DOBRZYNSKI RF
SHERIDAN MJ
Citation: Ra. Beveridge et al., A COMPARISON OF EFFICACY OF SARGRAMOSTIM (YEAST-DERIVED RHUGM-CSF) AND FILGRASTIM (BACTERIA-DERIVED RHUG-CSF) IN THE THERAPEUTIC SETTING OFCHEMOTHERAPY-INDUCED MYELOSUPPRESSION, Cancer investigation, 16(6), 1998, pp. 366-373
Authors:
BEVERIDGE RA
MILLER JA
KALES AN
BINDER RA
ROBERT NJ
HEISRATHEVANS J
KOCZYKSCRIPKA K
PASHKO S
NORGARD MJ
BARNES HM
TAYLOR WR
THOMPSON KA
SMITH LF
UENO WM
DOBRZYNSKI RF
WARREN RD
KATCHER D
BYRNE PJ
DUNNING DM
WINOKUR SH
LOCKEY JL
CAMBARERI RJ
BUTLER TP
MEISTER RJ
FIEGERT JM
Citation: Ra. Beveridge et al., RANDOMIZED TRIAL COMPARING THE TOLERABILITY OF SARGRAMOSTIM (YEAST-DERIVED RHUGM-CSF) AND FILGRASTIM (BACTERIA-DERIVED RHUG-CSF) IN CANCER-PATIENTS RECEIVING MYELOSUPPRESSIVE CHEMOTHERAPY, Supportive care in cancer, 5(4), 1997, pp. 289-298
Authors:
GREM JL
JORDAN E
ROBSON ME
BINDER RA
HAMILTON JM
STEINBERG SM
ARBUCK SG
BEVERIDGE RA
KALES AN
MILLER JA
WEISS RB
MCATEE N
CHEN A
GOLDSPIEL B
SOVER E
ALLEGRA CJ
Citation: Jl. Grem et al., PHASE-II STUDY OF FLUOROURACIL, LEUCOVORIN, AND INTERFERON ALFA-2A INMETASTATIC COLORECTAL-CARCINOMA, Journal of clinical oncology, 11(9), 1993, pp. 1737-1745
Authors:
MILLER JA
BUTLER T
BEVERIDGE RA
KALES AN
BINDER RA
SMITH LJ
UENO WM
MILKOVICH G
GOLDWATER S
MARION A
ERON L
MANGI R
BYRNES CA
LISS C
PASHKO S
Citation: Ja. Miller et al., EFFICACY AND TOLERABILITY OF IMIPENEM-CILASTATIN VERSUS CEFTAZIDIME PLUS TOBRAMYCIN AS EMPIRIC THERAPY OF PRESUMED BACTERIAL-INFECTION IN NEUTROPENIC CANCER-PATIENTS, Clinical therapeutics, 15(3), 1993, pp. 486-499